Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy

NCT05248334 is registered in ClinicalTrials.gov with Tianjin Medical University Eye Hospital as lead sponsor.

NCT NCT05248334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05248334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy
Lead sponsor
Tianjin Medical University Eye Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
April 10, 2022
Completion date
December 30, 2024
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic retinopathy, pars plana vitrectomy, postoperative recurrent vitreous hemorrhage, ranibizumab